drugset / Trial / NCT04009824
Evaluating the Safety and Immunogenicity of AGS-v PLUS, a Universal Mosquito-Borne Disease and Mosquito Control Vaccine
Phase 1
Completed
51 enrolled
National Institute of Allergy and Infectious Diseases (NIAID)
PepTcell Limited · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
The purpose of this study is to evaluate the safety and immunogenicity of AGS-v PLUS, a universal mosquito-borne disease and mosquito control vaccine, in healthy volunteers.
Timeline
- Start
- 2019-07-08
- Primary completion
- 2020-03-03
- Completion
- 2021-02-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AGS-v PLUS | Vaccine | 1012 ug | Subcutaneous |
| Subject | Aluminum hydroxide | Unknown | — | Subcutaneous |
| Subject | incomplete Freund's adjuvant | Other / unclassified | — | Subcutaneous |